In this international trial, participants who received the intervention engaged in HIV treatment, achieved viral suppression at higher rates, and died at half the rate of participants in a control group.
Researchers developed a tool that enables them to closely monitor HIV activity in key brain cells. The tool may accelerate the development of treatments for HIV in the brain.
Inhibiting mTOR, a regulatory protein complex, can prevent reactivation of latent HIV. Medications to inhibit mTOR might help people with HIV achieve and maintain undetectable HIV viral loads.
A gene variant appears to partially shield people whose behaviors entail high risk for exposure to human immunodeficiency virus (HIV) from becoming infected.